Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $97.33 Consensus PT from Brokerages

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have been assigned an average recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $97.3333.

ARWR has been the subject of a number of research reports. Leerink Partners increased their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a report on Wednesday, June 17th. Stifel Nicolaus initiated coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They set a “buy” rating and a $98.00 price objective for the company. B. Riley Financial increased their target price on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Morgan Stanley raised their price objective on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Finally, Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 27th.

Arrowhead Pharmaceuticals Stock Up 1.2%

Shares of ARWR stock opened at $86.64 on Friday. Arrowhead Pharmaceuticals has a 12 month low of $18.73 and a 12 month high of $95.49. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. The firm has a market cap of $12.20 billion, a PE ratio of -38.51 and a beta of 1.27. The stock has a 50 day moving average of $81.37 and a 200-day moving average of $72.15.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The company had revenue of $75.25 million during the quarter, compared to analyst estimates of $44.17 million. During the same quarter in the previous year, the business posted ($1.26) EPS. The company’s revenue was up 171.0% on a year-over-year basis. On average, equities analysts predict that Arrowhead Pharmaceuticals will post -3.51 EPS for the current year.

Institutional Trading of Arrowhead Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Tsfg LLC bought a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at $25,000. Optiver Holding B.V. lifted its holdings in Arrowhead Pharmaceuticals by 83.8% during the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 186 shares during the last quarter. Versant Capital Management Inc raised its stake in shares of Arrowhead Pharmaceuticals by 285.1% in the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 248 shares during the last quarter. Carolina Wealth Advisors LLC raised its stake in shares of Arrowhead Pharmaceuticals by 80.6% in the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 154 shares during the last quarter. Finally, iSAM Funds UK Ltd acquired a new position in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth approximately $29,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.